Email this article Family and polygenic hypercholesterolemia: similarities and differencies by long-term follow-up
- Authors: Lipovetskiy BM, Lipovetsky BM
- Issue: Vol 81, No 1 (2009)
- Pages: 61-63
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33396
- ID: 33396
Cite item
Full Text
Abstract
Aim. Detection and analysis of similarities and differences in patients with family and polygenic hypercholesterolemia (FHCE and PHCE).
Material and methods. The study included 100 patients with FHCE and 80 PHCE patients with LDLP cholesterol level at least 4.3 mmol/l (170 mg/dl).
Results. The patients differed by age, gender, severity of hypercholesterolemia, clinical symptoms. Half of PHCE patients had myocardial infarction, 18% had angina pectoris, 29% cerebrovascular events. The disease was asymptomatic in 19% FHCE patients, 33% had myocardial infarction, 15% - angina pectoris, 12% - cerebrovascular events, 9% - aortic problems. Total mortality in both groups was similar - 32 and 33%. Long-term treatment with statins reduced lethality twice both in FHCE and PHCE. Adequate statin therapy prolonged life of the patients by 11 years, on the average.
Conclusion. Regular treatment of patients with hypercholesterolemia reduces lethality and prolong their life span.
Material and methods. The study included 100 patients with FHCE and 80 PHCE patients with LDLP cholesterol level at least 4.3 mmol/l (170 mg/dl).
Results. The patients differed by age, gender, severity of hypercholesterolemia, clinical symptoms. Half of PHCE patients had myocardial infarction, 18% had angina pectoris, 29% cerebrovascular events. The disease was asymptomatic in 19% FHCE patients, 33% had myocardial infarction, 15% - angina pectoris, 12% - cerebrovascular events, 9% - aortic problems. Total mortality in both groups was similar - 32 and 33%. Long-term treatment with statins reduced lethality twice both in FHCE and PHCE. Adequate statin therapy prolonged life of the patients by 11 years, on the average.
Conclusion. Regular treatment of patients with hypercholesterolemia reduces lethality and prolong their life span.
References
- Goldstein J., Hobbs H., Brown M. Familial hypercholesterolemia In: Scriver C. et al., eds. The metabolic basis of inherited diseases. New York; 1995. 1981-2030.
- Мандельштам М. Ю. Что дало изучение семейной гиперхолестеринемии для понимания генетики дислипидемий. Мед. генетика 2003; 2(12): 509-518.
- Липовецкий Б. М., Шестов Д. Б., Плавинская С. И. и др. Эпидемиологические аспекты ИБС, артериальной гипертензии и атерогенных изменений липидного состава крови среди мужского и женского населения Ленинграда 20-69 лет. Тер. арх. 1984; 4: 44-48.
- Пузырев В. П. Генетика мультифакториальных заболеваний: между прошлым и будущим Мед. генетика 2003; 2(12): 498-508.
- Halushka M., Fan J., Bently K. et al. Patterns of singlenucleotide polymorphisms in candidate genes for blood-pressure homeostasis Nat. Genet. 1999; 22: 239-247.
- Тимофеева Ф. И., Горюнова Л. Е., Хаспеков Г. Л. и др. Фармакогенетика, фармакогеномика в свете проблем, связанных с эссенциальной артериальной гипертонией Кардиол. вестн. 2007; 2(1): 5-12.
- Miserez A., Miller P., Barella S. et al. Sterol-regulatory, element-binding protein-2 contributes to polygenic hypercholesterolaemia. Atherosclerosis 2002; 164(1): 15-26.
- Климов А. Н. Атеросклероз. В кн.: "Превентивная кардиология". M.; 1987. 239-316.
- Аронов Д. М. Плеотропные эффекты статинов. Рус. мед. журн. 2001; 9(13-14): 2-7.
- Palinski W., Napoli C. Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler. Thromb. Vase. Biol. 2002; 22: 1745.
- Липовецкий Б. М. Эпидемиология атеросклероза и артериальной гипертензии. СПб.; 2004.
Supplementary files
